Dobecure

Dobecure is a clinical-stage biotechnology company based in Madrid, Spain, specializing in the development of treatments for vascular and inflammatory eye diseases. The company's primary focus is on the use of potassium dobesilate, a small molecule inhibitor of fibroblast growth factor (FGF), to treat conditions such as diabetic retinopathy and age-related macular degeneration. By targeting the FGF pathway, Dobecure aims to provide a non-invasive, topical alternative to the current standard of care, which often involves frequent intravitreal injections. Their lead program has progressed into Phase 2 clinical trials, demonstrating the potential to prevent vision loss by addressing the underlying angiogenic and inflammatory drivers of retinal disease. The company's research is rooted in decades of study regarding the role of growth factors in pathological neovascularization.